Back
Brainstorm Cell Therapeutics Quote, Financials, Valuation and Earnings
AI DIVIDENDS: No. 1 Way to Collect Passive Income
Click here to get it for free.
Sell
7
BCLI
Brainstorm Cell Therapeutics
Last Price:
1.91
Seasonality Move:
2.27%
7 Day Trial
ALL ACCESS PASS
$
7
Investing Today: The Best Way To Grow A Small Account
In his free guide, expert Joe Duffy reveals... click here to read on...Brainstorm Cell Therapeutics Price Quote
$1.91
+0.04 (+2.14%)
(Updated: November 1, 2024 at 10:25 AM ET)
Brainstorm Cell Therapeutics Key Stats
Sell
7
Brainstorm Cell Therapeutics (BCLI)
is a Sell
Day range:
$1.81 - $1.95
52-week range:
$1.81 - $11.89
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0%
Volume:
34.1K
Avg. volume:
75.2K
1-year change:
-18.52%
Market cap:
$9.9M
Revenue:
$0
EPS:
$-3.45
How Much Does Brainstorm Cell Therapeutics Make?
Data Unavailable
Is Brainstorm Cell Therapeutics Growing As A Company?
Data Unavailable
Brainstorm Cell Therapeutics Stock Price Performance
-
Did Brainstorm Cell Therapeutics Stock Go Up Last Month?
Brainstorm Cell Therapeutics share price went down by -45.87% last month -
Did BCLI's Share Price Rise Over The Last Year?
BCLI share price fell by -18.52% over the past 1 year
What Is Brainstorm Cell Therapeutics 52-Week High & Low?
-
What Is Brainstorm Cell Therapeutics’s 52-Week High Share Price?
Brainstorm Cell Therapeutics has traded as high as $11.89 over the past 52 weeks -
What Is Brainstorm Cell Therapeutics’s 52-Week Low Share Price?
Brainstorm Cell Therapeutics has traded as low as $1.81 over the past 52 weeks
Brainstorm Cell Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Brainstorm Cell Therapeutics?
-
How Much Debt Does Brainstorm Cell Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Brainstorm Cell Therapeutics Have?
Cash and short term investments quarterly total is $3.5M -
What Is Brainstorm Cell Therapeutics’s Book Value Per Share?
Book value per share is -0.66
Is Brainstorm Cell Therapeutics Cash Flow Positive?
-
What Is BCLI Cash Flow From Operations?
Cash flow from operations (TTM) is -$14.4M -
What Is Brainstorm Cell Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $17.4M -
What Is Brainstorm Cell Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $184K
Brainstorm Cell Therapeutics Return On Invested Capital
Data Unavailable
Brainstorm Cell Therapeutics Earnings Date & Stock Price
-
What Is Brainstorm Cell Therapeutics's Stock Price Today?
A single share of BCLI can be purchased today for 1.87 -
What Is Brainstorm Cell Therapeutics’s Stock Symbol?
Brainstorm Cell Therapeutics trades on the nasdaq under the ticker symbol: BCLI -
When Is Brainstorm Cell Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Brainstorm Cell Therapeutics is scheduled on November 14, 2024 -
When Is BCLI's next ex-dividend date?
Brainstorm Cell Therapeutics's next ex-dividend date is November 1, 2024 -
How To Buy Brainstorm Cell Therapeutics Stock?
You can buy Brainstorm Cell Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Brainstorm Cell Therapeutics Competitors
-
Who Are Brainstorm Cell Therapeutics's Competitors?
Below is a list of companies who compete with Brainstorm Cell Therapeutics or are related in some way:
Brainstorm Cell Therapeutics Dividend Yield
-
What Is BCLI Dividend Yield?
Brainstorm Cell Therapeutics’s dividend yield currently is 0% -
What Is Brainstorm Cell Therapeutics’s Payout Ratio?
Brainstorm Cell Therapeutics’s payout ratio is 0% -
When Did Brainstorm Cell Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 1, 2024 -
What Is Brainstorm Cell Therapeutics’s Dividend Per Share?
Brainstorm Cell Therapeutics pays a dividend of $0.00 per share
Brainstorm Cell Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -33.33% |
| Revenue: | 0% | 0% |
Analyst Recommendations
| Buy Recommendations: | 0 |
|---|---|
| Hold Recommendations: | 0 |
| Sell Recommendations: | 0 |
| Price Target: | 22.84 |
| Upside from Last Price: | 1121.21% |